

Abstract

When a host system faces infection, immediate multipurpose responses become necessary, as the host must be ready to defend against any type of pathogen. Ubiquitous defense proteins such as the Guanylate Binding Proteins (GBPs) are vital in this effort. GBPs are interferon- γ induced proteins that bind to guanosine molecules as a substrate and can defend against microbial invasion. Humans have seven paralogs of GBP in their genome, each with an N-terminal GTPase domain, a middle domain, and a C-terminal effector domain. In this study, we have taken a deeper look into human GBP4.

Though all seven paralogs have similar functions, they retain stark differences in their nucleoside-binding capabilities and signaling. To understand the molecular basis for these differences, we examined the protein sequences of each human GBP paralog and compared them to GBP4. In doing so, we can determine relationships between structure and function and discover conserved residues, domain features, and functional motifs across each human GBP. Coinciding with the protein analysis, we have also purified GBP4's GTPase domain and N-terminus to middle domain to homogeneity to assay their ability to bind to different guanosine nucleosides.

Understanding GBP4's immunological niche is critical, as previous studies have displayed GBP4's relevance in innate immune signaling. Currently, there are no published studies of the biochemical or structural features of GBP4. Characterizing GBP4 is a major step toward comprehending the GBPs in their entirety and utilizing them in future medicine.

Analysis of key motifs

GBP4	60	MGERTLHAAVPTPGY	PESE	SI	MM	AP	IC	LV	EN	QE	EQ	LV	NS	KA	LE	IL	DK	IS	QP	VV	VV	AI	VG	
GBP6	45	ME	SG	KM	AP	VC	LV	EN	NE	QL	VN	QA	IQ	LE	KI	SQ	PV	VV	AI	VG				
GBP7	45	MA	SE	IH	MP	GP	VC	LV	EN	NE	QL	VN	QA	IQ	LE	KI	SQ	PV	VV	AI	VG			
GBP5	45	MA	LE	IH	MS	DP	MC	LI	EN	FE	NQ	LV	NS	EA	LE	IL	SA	IT	QP	VV	VV	AI	VG	
GBP1	45	MA	SE	IH	MT	GP	MC	LI	EN	NG	LV	NS	EA	LE	IL	SA	IT	QP	VV	VV	AI	VG		
GBP3	45	MA	PE	IH	MT	GP	MC	LI	EN	NG	LV	NS	EA	LE	IL	SA	IT	QP	VV	VV	AI	VG		
GBP2	45	MA	PE	IH	MT	GP	MC	LI	EN	NG	LV	NS	EA	LE	IL	SA	IT	QP	VV	VV	AI	VG		

End of G-domain


GBP4	299	GI	IV	TG	KRL	GTL	VV	TY	VD	AIN	SG	AV	PC	LE	NA	VT	AL	AQ	LE	NP	AA	VQ	RA	AD	HYS	QQ	MA	QQL	R	358		
GBP6	284	GI	TV	TG	NRL	GTL	AV	TY	VE	AIN	SG	AV	PC	LE	NA	VT	AL	AQ	RE	NS	AA	VQ	RA	SD	Y	QQ	MA	Q	RV	K	343	
GBP7	284	GI	LV	TG	NRL	GML	VE	TY	LD	AIN	SG	AT	PC	LE	NA	MA	VL	AQ	CE	NS	AA	VQ	RA	AN	HYS	QQ	MA	Q	Q	V	R	343
GBP5	283	GI	MV	NG	SRL	KNL	VL	TY	VA	IN	SS	GD	PC	LE	NA	VL	AL	AQ	RE	NS	AA	VQ	KA	IA	H	Y	QQ	M	G	Q	V	342
GBP1	285	GI	QV	NG	PR	LES	LV	TY	VA	IN	SS	GD	PC	LE	NA	VL	AL	AQ	RE	NS	AA	VQ	KA	IA	H	Y	QQ	M	G	Q	V	344
GBP3	283	GI	KV	NG	PR	LES	LV	TY	VA	IN	SS	GD	PC	LE	NA	VL	AL	AQ	RE	NS	AA	VQ	KA	IA	H	Y	QQ	M	G	Q	V	342
GBP2	283	GI	PV	NG	PR	LES	LV	TY	VA	IN	SS	GD	PC	LE	NA	VL	AL	AQ	RE	NS	AA	VQ	KA	IA	H	Y	QQ	M	G	Q	V	342

End of middle domain

GBP4	479	LQ	SQ	VV	EE	SIL	QSD	KAL	T	GE	KA	IA	AA	ER	AM	KE	AA	EE	KE	QEL	RE	KQ	KE	QQ	MM	E	A	Q	E	R	S	F	538																											
GBP6	464	LE	SQ	MV	IE	EE	SIL	QSD	KAL	T	RE	KA	VA	AV	DR	AK	KE	AA	EE	KE	QEL	LK	QK	LE	QQ	QQ	ME	A	Q	V	K	S	R	523																										
GBP7	464	LQ	SQ	VV	IE	EE	SIL	QSD	KAL	T	GE	KA	IA	AA	QK	AK	KE	AA	EE	KE	QEL	RQ	KQ	KE	QQ	MM	E	A	Q	E	R	S	F	523																										
GBP5	463	LK	SK	ES	V	SH	AIL	QTD	QAL	T	E	K	K	K	E	A	Q	V	K	A	E	A	E	A	E	A	E	A	E	A	E	A	E	R	L	H	522																							
GBP1	465	LK	SK	E	S	M	T	D	A	I	L	Q	T	D	Q	T	L	T	E	K	E	K	E	T	E	V	E	R	V	K	A	E	S	A	Q	A	S	A	K	M	L	Q	E	M	Q	R	K	N	E	Q	M	M	E	Q	K	E	R	S	Y	524
GBP3	463	LK	SK	E	S	V	T	D	A	I	L	Q	T	D	Q	I	L	T	E	K	E	K	E	T	E	V	E	C	V	K	A	E	S	A	Q	A	S	A	K	M	V	E	E	M	Q	I	K	Y	Q	M	M	E	E	K	E	S	Y	522		
GBP2	463	LE	S	K	E	D	V	A	D	A	L	L	Q	T	D	Q	S	L	S	E	K	E	K	A	T	E	V	E	R	I	K	A	E	S	A	E	A	A	K	M	L	E	E	I	Q	K	N	E	E	M	M	E	Q	K	E	S	Y	522		


GBP6	524	KE	NI	AQ	L	KE	KL	Q	M	E	R	E	H	L	RE	Q	I	M	L	E	H	T	Q	K	V	Q	N	D	W	L	H	E	G	F	K	K	K	Y	E	M	N	A	E	I	S	Q	F	K	R	M	I	D	583									
GBP4	539	QE	Y	MA	Q	M	E	K	K	L	E	E	R	N	L	R	E	H	E	R	L	L	K	H	K	L	K	V	Q	E	E	M	L	K	E	F	Q	K	K	S	E	Q	L	N	K	E	I	N	Q	L	K	E	K	I	E	598						
GBP7	524	Q	E	N	I	A	Q	L	K	K	K	M	E	R	E	R	E	N	Y	M	R	E	L	R	K	M	L	S	H	K	M	K	V	L	E	E	L	T	E	G	F	K	E	I	F	S	L	N	E	E	I	N	R	L	K	E	Q	I	E	583		
GBP5	523	Q	E	V	R	Q	M	E	---	---	I	A	K	Q	N	W	L	A	E	Q	Q	K	M	Q	E	Q	M	Q	E	Q	A	A	L	S	T	T	F	Q	A	Q	N	R	S	L	S	E	L	Q	H	A	Q	R	T	V	N	578						
GBP1	525	Q	E	H	L	K	Q	L	T	E	K	M	E	N	D	R	V	Q	L	L	K	E	Q	E	R	T	L	A	L	K	L	Q	E	Q	E	L	L	K	E	G	F	Q	K	S	R	I	M	K	N	E	I	Q	D	L	Q	T	K	M	R	584		
GBP3	523	Q	E	H	V	K	Q	L	T	E	K	M	E	R	A	R	A	L	L	E	E	Q	E	K	T	L	T	S	K	L	Q	E	Q	A	R	V	L	K	E	R	C	Q	G	E	S	T	Q	L	Q	N	E	I	Q	K	L	Q	K	T	L	K	582	
GBP2	523	Q	E	H	V	K	Q	L	T	E	K	M	E	R	D	R	A	Q	L	M	A	E	Q	E	K	T	L	A	L	K	L	Q	E	Q	E	R	L	L	K	E	G	F	E	N	E	S	K	R	L	Q	K	D	I	W	D	I	Q	M	R	S	K	582

The G-domain is a highly conserved region across the human GBPs, with minor variations in the body of the G-domain. However, GBP4 contains a sequence of fifteen bps positioned before the start site of any other human GBP. This mildly hydrophobic motif is predicted to extend outside of the main G-domain structure










At the start of the middle domains, similar conservation can be observed, however, the variation increases as the sequence gets closer to the effector domain. The effector domains of each GBP are highly variable, especially among different "branches" of GBPs in the phylogeny.

The effector domain becomes disarrayed and specialized across the GBPs, however, a pattern can be observed even in this highly unconserved region: GBP4 and GBP7 still retain high fidelity to each other, as do GBP1 and GBP3. This relatedness is reflected in the GBP phylogeny, which also reflects that these pairs motifs happen to be the most unrelated to each other as well.



Purification and Hydrolysis Assay



Next Steps

- The unique 15 bp at the start of GBP4 could be examined further to discover functional characteristics.
- The results of the sequence alignment will be further corroborated with positional information of conserved and different sequences.
- The full length of GBP4 cannot be successfully expressed in bacterial cells. To circumvent this, insect cells will be utilized to grow the protein for further assays and the creation of a confirmable structural model.
- Further trials of the Malachite Green Assay will be performed to achieve more stable and conclusive results